Eloxatine adjuvant therapy for advanced colorectal cancer.

The KFDA approved Sanofi-Aventis' Eloxatin, a colorectal cancer treatment, on June 15 for an adjuvant treatment in combination with the standard therapy after the surgical operation of advanced colorectal patient, which was the first in its new adjuvant therapy of the colorectal patients after the standard therapy (5-FU/LV) in practice during the past 10 years.

Eloxatine was approved by the ...